'anonymous' 'anonymous'
Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles

CR109083

A study of ad26.cov2.s and influenza vaccines in healthy adults
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT05091307
Recrutement fermé
Dernière modification : 2025/05/24
Type de recherche

Interventionnel

Médicament expérimental

PHASE3


Population cible

Condition médicale (spécialité visée)

Donnée non disponible

Profil des participants

Limites d'âge
minimum : 18 ans
Sexe(s) des participants

ALL

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

* Participant must be healthy, in the investigator's clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. Participants may have underlying illnesses, as long as the symptoms and signs are medically controlled
* Participant either received complete primary vaccination with an authorized/licensed coronavirus disease-2019 (COVID-19) vaccine (completed greater than or equal to \[\>=\] 6 months prior to the last vaccination received against COVID-19) or is COVID-19 vaccine-naive
* All participants who were born female and are of childbearing potential must: a. Have a negative highly sensitive urine pregnancy test at screening, b. Have a negative highly sensitive urine pregnancy test on the day of vaccination prior to each study vaccine administration
* Participant agrees to not donate or receive bone marrow, blood, and blood products from the administration of the study vaccine until 3 months after receiving the study vaccines
* Participant must be willing to provide verifiable identification to be contacted and to contact the investigator during the study

Exclusion Criteria:

* Participant has a history of malignancy within 1 year before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancies considered cured with minimal risk of recurrence per investigator's clinical judgment)
* Participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature \>= 38.0 degrees celsius (ºC) (100.4 degrees fahrenheit \[°F\]) within 24 hours prior to the planned dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator
* Participant has history of thrombosis with thrombocytopenia syndrome (TTS) or heparin-induced thrombocytopenia and thrombosis (HITT)
* Participant has history of capillary leak syndrome
* Participant received a licensed/registered severe acute respiratory syndrome coronavirus(-2) (SARS-CoV-2) vaccine less than 6 months prior to first study vaccination (other than study vaccination)
* Participant has a history of any neurological disorders or seizures including Guillain-Barre syndrome, with the exception of febrile seizures during childhood

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-dose (SD) Influenza Vaccine and Placebo Participants aged greater than or equal to (\>=) 18 years will receive a single intramuscular (IM) injection of Ad26.COV2.S and a seasonal Q SD influenza vaccine on Day 1 and placebo on Day 29. Donnée non disponible
  • Inconnu
  • Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S Participants aged \>=18 years will receive a single IM injection of placebo and a seasonal Q SD influenza vaccine on Day 1 followed by Ad26.COV2.S on Day 29. Donnée non disponible
  • Inconnu
  • Group 3: Ad26.COV2.S + Q High-dose (HD) Influenza Vaccine and Placebo Participants aged \>=65 years will receive a single IM injection of Ad26.COV2.S and a seasonal Q HD influenza vaccine on Day 1 followed by placebo on Day 29. Donnée non disponible
  • Inconnu
  • Group 4: Placebo + Q HD Influenza Vaccine and Ad26.COV2.S Participants aged \>=65 years will receive a single IM injection of placebo and a seasonal Q HD influenza vaccine on Day 1 followed by Ad26.COV2.S on Day 29. Donnée non disponible
  • Inconnu
  • Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-dose (SD) Influenza Vaccine and Placebo
    État du recrutement
    unknown
    Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S
    État du recrutement
    unknown
    Group 3: Ad26.COV2.S + Q High-dose (HD) Influenza Vaccine and Placebo
    État du recrutement
    unknown
    Group 4: Placebo + Q HD Influenza Vaccine and Ad26.COV2.S
    État du recrutement
    unknown
    Données à jour depuis : 24 mai 2025

    Description de l'étude

    Résumé de l'étude

    The purpose of this study is to demonstrate the non-inferiority (NI) of the humoral immune response of the 4 influenza vaccine strains after concomitant administration of the Ad26.COV2.S vaccine and a seasonal quadrivalent standard-dose influenza vaccine versus the administration of a seasonal quadrivalent standard-dose influenza vaccine administered alone; and to demonstrate the NI of the binding antibody response after concomitant administration of Ad26.COV2.S vaccine and a seasonal quadrivalent standard-dose influenza vaccine versus the administration of Ad26.COV2.S vaccine administered alone.

    Source : Importé depuis le centre

    Severe acute respiratory syndrome coronavirus(-2) (SARS CoV-2) is a highly transmissible and pathogenic coronavirus that has spread rapidly and globally and Influenza is a worldwide public health problem, responsible for significant morbidity and mortality. Ad26.COV2.S (also known as VAC31518, JNJ-78436735) is a monovalent vaccine composed of a recombinant, replication-incompetent human adenovirus type 26 (Ad26) vector, constructed to encode SARS-CoV-2 spike (S) protein, stabilized in its prefusion conformation. The seasonal influenza vaccines to be used in this study are quadrivalent (standard dose) and quadrivalent (high-dose) or equivalent formulated. The aim is to demonstrate the concomitant administration of the Ad26.COV2.S vaccine and a seasonal quadrivalent influenza vaccine (standard-dose) is non-inferior than the administration of either seasonal quadrivalent influenza vaccine (standard-dose) alone as measured by HI titers against each of the 4 influenza vaccine strains at 28 days after the administration of a quadrivalent seasonal influenza vaccine or Ad26.COV2.S vaccine alone as measured by Spiked-Enzyme-linked Immunosorbent Assay (S-ELISA) antibody titers at 28 days after the administration of the Ad26.COV2.S vaccine. This study consists of 3 phases: screening phase (Day -28 to 1), treatment phase (vaccination visits on Days 1 and 29), and a follow-up phase (28 days after each vaccination). Some of safety assessments will include physical examination, vital signs, clinical safety laboratory assessments, pregnancy testing, monitoring of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESI). The total duration of the study is up to 7-8 months.

    Note: The Informed Consent Form dated 25-Mar-2022 is final version of the study MASTER ICF, used by local countries to prepare the local language version of the ICF, which have been approved by the Ethics Committees. And the highlighted text in the ICF document are the guidance for country specific adaptation.

    Source : Importé depuis le centre

    Sites

    Centres participants

      10 affichés sur 22 centres
    • AMR FORT MYERS CLINICAL PHYSIOLOGY ASSOCIATES, AN AMR COMPANY

      Fort myers

      FLORIDA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • CAROLINA INSTITUTE FOR CLINICAL RESEARCH

      Fayetteville

      NORTH CAROLINA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • CENTRUM MEDYCZNE PRATIA POZNAN

      Skorzewo

      WIELKOPOLSKIE, POLAND

      Recrutement local
      État du recrutement: FERMÉ
    • CLINICAL RESEARCH CONSORTIUM, AN AMR COMPANY

      Las vegas

      NEVADA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • CLINICAL RESEARCH OF SOUTH FLORIDA, AN AMR COMPANY

      Coral gables

      FLORIDA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • FIEL FAMILY AND SPORTS MEDICINE CLINICAL RESEARCH ADVANTAGE

      Tempe

      ARIZONA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • I.D. CARE, INC.

      Hillsborough

      NEW JERSEY, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • INSTITUTE OF TROPICAL MEDICINE ANTWERP

      Antwerpen

      BELGIUM

      Recrutement local
      État du recrutement: FERMÉ
    • MEDISPHERE MEDICAL RESEARCH CENTER, LLC

      Evansville

      INDIANA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • MERIDIAN CLINICAL RESEARCH, LLC

      Norfolk

      NEBRASKA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 24 mai 2025
    Données à jour depuis : 28 mai
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT05091307